Maropitant Citrate Tablets are recommended for use in dogs 8 weeks and older.
For
Prevention of Acute Vomiting
Administer Maropitant Citrate Tablets
orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily
for up to 5 consecutive days.
Maropitant Citrate Tablets may be
used interchangeably with Maropitant Injectable Solution for once daily
dosing for the prevention of acute vomiting.
For
Prevention of Vomiting Due to Motion Sickness
Administer Maropitant Citrate Tablets
orally at a minimum dose of 8 mg/kg (3.6 mg/lb) body weight once daily
for up to 2 consecutive days. Dogs should be fasted 1
hour prior to administration of
Maropitant Citrate Tablets. Administer Maropitant Citrate Tablets 2 hours prior to travel.
Warnings:
Not for use in humans. Keep out of reach of children. In case of
accidental ingestion, seek medical advice. Topical exposure may elicit
localized allergic skin reactions in some individuals. Repeated or
prolonged exposure may lead to skin sensitization. Wash hands with soap
and water after administering drug.
Maropitant Citrate is also an ocular irritant.
In case of accidental eye exposure, flush with water for 15 minutes and
seek medical attention.
In puppies younger than 11
weeks of age, histological evidence of bone marrow hypoplasia was seen
at higher frequency and greater severity in puppies treated with
Maropitant Citrate than in control puppies. In puppies 16 weeks and older, bone marrow
hypoplasia was not seen.
Precautions:
The safe use of Maropitant Citrate Tablets has not been evaluated in dogs used for
breeding, pregnant or lactating bitches, dogs with gastrointestinal
obstruction, or dogs that have ingested toxins. Use with caution in dogs
with hepatic dysfunction. Use with caution with other medications that
are highly protein bound. The concomitant use of
Maropitant Citrate with other
protein bound drugs has not been studied in dogs. Commonly used protein
bound drugs include NSAIDs, cardiac, anticonvulsant and behavioral
medications. The influence of concomitant drugs that may inhibit
metabolism of
Maropitant Citrate has not been evaluated. Drug compatibility should
be monitored in patients requiring adjunctive therapy.
Federal (USA) law restricts this drug to use by or on the order of a
licensed veterinarian
